Paul A Cohen1, Cassandra B Nichols, Lyn Schofield, Steven Van Der Werf, Nicholas Pachter. 1. *St John of God Hospital Bendat Family Comprehensive Cancer Centre, Subiaco, Western Australia; †School of Women's and Infants' Health, University of Western Australia; ‡Institute for Health Research, University of Notre Dame Australia, Fremantle, Western Australia; §Genetics Services of Western Australia, King Edward Memorial Hospital, Subiaco, Western Australia; ∥Inherited Cancer Connect Partnership (ICCon); ¶School of Paediatrics and Child Health, University of Western Australia; and #School of Medicine and Pharmacology, University of Western Australia.
Abstract
OBJECTIVES: The objectives of this work were to determine the proportion of eligible patients with ovarian cancer discussed at a gynecologic oncology tumor board who were referred for counseling and BRCA mutation testing; to compare referral rates before genetics attendance at the tumor board to referral rates after genetics attendance; and to ascertain the proportions of women with germline BRCA mutations. MATERIALS AND METHODS: Eligible cases were identified from the minutes of the weekly Western Australian gynecologic oncology tumor board from July 1, 2013 to June 30, 2015.Patients with ovarian cancer who met eligibility criteria for genetics referral were identified and checked against the records of the genetic services database to ascertain whether a referral was received. Outcomes including attendance for counseling and results of mutation testing were analyzed. RESULTS: Two hundred sixty-one patients were eligible for referral during the 24-month study period. One hundred six patients (40.6%) were referred for counseling and germline mutation testing. Of the eligible patients, 26.7% were referred in the 12 months before genetics attendance at the tumor board compared to 51.7% of the eligible patients in the 12 months after genetics attendance (P ≤ 0.0001). Ninety-seven patients were offered BRCA mutation testing, and 73 underwent testing with 65 results reported to date. Twenty-two patients (33.8 %) tested positive for a germline BRCA mutation. CONCLUSIONS: Patients with ovarian cancer had a high rate of BRCA mutations. Attendance of a genetics service at a tumor board was associated with an improved rate of referral of patients for genetic counseling and BRCA mutation testing.
OBJECTIVES: The objectives of this work were to determine the proportion of eligible patients with ovarian cancer discussed at a gynecologic oncology tumor board who were referred for counseling and BRCA mutation testing; to compare referral rates before genetics attendance at the tumor board to referral rates after genetics attendance; and to ascertain the proportions of women with germline BRCA mutations. MATERIALS AND METHODS: Eligible cases were identified from the minutes of the weekly Western Australian gynecologic oncology tumor board from July 1, 2013 to June 30, 2015.Patients with ovarian cancer who met eligibility criteria for genetics referral were identified and checked against the records of the genetic services database to ascertain whether a referral was received. Outcomes including attendance for counseling and results of mutation testing were analyzed. RESULTS: Two hundred sixty-one patients were eligible for referral during the 24-month study period. One hundred six patients (40.6%) were referred for counseling and germline mutation testing. Of the eligible patients, 26.7% were referred in the 12 months before genetics attendance at the tumor board compared to 51.7% of the eligible patients in the 12 months after genetics attendance (P ≤ 0.0001). Ninety-seven patients were offered BRCA mutation testing, and 73 underwent testing with 65 results reported to date. Twenty-two patients (33.8 %) tested positive for a germline BRCA mutation. CONCLUSIONS:Patients with ovarian cancer had a high rate of BRCA mutations. Attendance of a genetics service at a tumor board was associated with an improved rate of referral of patients for genetic counseling and BRCA mutation testing.
Authors: Shama Virani; Glauco Baiocchi; David Bowtell; Citadel J Cabasag; Kathleen R Cho; Renée T Fortner; Keiichi Fujiwara; Jae-Weon Kim; Martin Köbel; Jean-Emmanuel Kurtz; Douglas A Levine; Usha Menon; Barbara M Norquist; Paul D P Pharoah; Anil K Sood; Shelley T Tworoger; Nicolas Wentzensen; Stephen J Chanock; Paul Brennan; Britton Trabert Journal: Carcinogenesis Date: 2021-06-21 Impact factor: 4.944
Authors: Rachel Delahunty; Linh Nguyen; Stuart Craig; Belinda Creighton; Dinuka Ariyaratne; Dale W Garsed; Elizabeth Christie; Sian Fereday; Lesley Andrews; Alexandra Lewis; Sharne Limb; Ahwan Pandey; Joy Hendley; Nadia Traficante; Natalia Carvajal; Amanda B Spurdle; Bryony Thompson; Michael T Parsons; Victoria Beshay; Mila Volcheck; Timothy Semple; Richard Lupat; Kenneth Doig; Jiaan Yu; Xiao Qing Chen; Anna Marsh; Christopher Love; Sanela Bilic; Maria Beilin; Cassandra B Nichols; Christina Greer; Yeh Chen Lee; Susan Gerty; Lynette Gill; Emma Newton; Julie Howard; Rachel Williams; Christie Norris; Andrew N Stephens; Erin Tutty; Courtney Smyth; Shona O'Connell; Thomas Jobling; Colin J R Stewart; Adeline Tan; Stephen B Fox; Nicholas Pachter; Jason Li; Jason Ellul; Gisela Mir Arnau; Mary-Anne Young; Louisa Gordon; Laura Forrest; Marion Harris; Karen Livingstone; Jane Hill; Georgia Chenevix-Trench; Paul A Cohen; Penelope M Webb; Michael Friedlander; Paul James; David Bowtell; Kathryn Alsop Journal: J Clin Oncol Date: 2022-03-09 Impact factor: 50.717
Authors: Jeanna M McCuaig; Tracy L Stockley; Patricia Shaw; Michael Fung-Kee-Fung; Alon D Altman; James Bentley; Marcus Q Bernardini; Beatrice Cormier; Hal Hirte; Katharina Kieser; Andree MacMillan; Wendy S Meschino; Karen Panabaker; Renee Perrier; Diane Provencher; Kasmintan A Schrader; Kimberly Serfas; Eva Tomiak; Nora Wong; Sean S Young; Walter Henri Gotlieb; Paul Hoskins; Raymond H Kim Journal: J Med Genet Date: 2018-07-24 Impact factor: 6.318